Beth L Nordstrom

Summary

Affiliation: United BioSource Corporation
Country: USA

Publications

  1. doi Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention
    Beth L Nordstrom
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
    Am J Cardiovasc Drugs 13:263-71. 2013
  2. doi Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents
    Beth L Nordstrom
    United BioSource Corporation, Lexington, Massachusetts, USA
    Arthritis Care Res (Hoboken) 64:1357-64. 2012
  3. doi Identification of metastatic cancer in claims data
    Beth L Nordstrom
    United BioSource Corporation, Lexington, MA, USA
    Pharmacoepidemiol Drug Saf 21:21-8. 2012
  4. ncbi Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter
    Beth L Nordstrom
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
    J Manag Care Pharm 14:858-69. 2008
  5. doi Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism
    Beth L Nordstrom
    United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 27:1973-85. 2011
  6. doi Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006
    Weixiu Luo
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington Office Park, Lexington, MA 02420, USA
    Clin Ther 30:2423-35. 2008
  7. doi Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin
    Beth L Nordstrom
    Evidera, Lexington, MA, USA
    Curr Med Res Opin 31:439-47. 2015

Detail Information

Publications7

  1. doi Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention
    Beth L Nordstrom
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
    Am J Cardiovasc Drugs 13:263-71. 2013
    ..To measure the adherence and persistence of patients with acute coronary syndrome (ACS) initiating prasugrel after percutaneous coronary intervention (PCI)...
  2. doi Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents
    Beth L Nordstrom
    United BioSource Corporation, Lexington, Massachusetts, USA
    Arthritis Care Res (Hoboken) 64:1357-64. 2012
    ..To estimate the relative risk of incident cancer diagnosis among patients with juvenile idiopathic arthritis (JIA) compared to patients without JIA...
  3. doi Identification of metastatic cancer in claims data
    Beth L Nordstrom
    United BioSource Corporation, Lexington, MA, USA
    Pharmacoepidemiol Drug Saf 21:21-8. 2012
    ..To develop algorithms to identify metastatic cancer in claims data, using tumor stage from an oncology electronic medical record (EMR) data warehouse as the gold standard...
  4. ncbi Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter
    Beth L Nordstrom
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington, MA 02420, USA
    J Manag Care Pharm 14:858-69. 2008
    ....
  5. doi Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism
    Beth L Nordstrom
    United BioSource Corporation, Lexington, MA 02420, USA
    Curr Med Res Opin 27:1973-85. 2011
    ..The current study was conducted to determine the association between international normalized ratio (INR) levels and VTE outcomes...
  6. doi Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006
    Weixiu Luo
    United BioSource Corporation, 430 Bedford Street, Suite 300, Lexington Office Park, Lexington, MA 02420, USA
    Clin Ther 30:2423-35. 2008
    ..Because of poorer disease outcomes and increased risk of adverse events associated with ESAs in recent studies, the use of ESAs has been increasingly restricted in practice guidelines in the years 2007 and 2008...
  7. doi Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin
    Beth L Nordstrom
    Evidera, Lexington, MA, USA
    Curr Med Res Opin 31:439-47. 2015
    ..This study examines the association between INR levels and VTE recurrence among warfarin-treated patients...